April 13, 2023, 10AM EDT
Join Marc Ellison, Instem’s Director of SEND and author
of the Sensible SEND blog, as he discusses and reflects on the
most pressing issues, challenges, and opportunities regarding SEND.
Discover how in silico methods can be used to assess safety
based on the drug target biology as well as the chemical.
We are excited to introduce SEND Advantage™ Services. Offering study conversions, compliance services and consulting, our new and refreshed services have been designed to help organizations maintain SEND compliance and more. Watch our on-demand video right now.
Instem CSO, Dr Gordon Baxter, was recently interviewed by Drug Target Review
for an in-depth editorial on Target Safety Assessment.
Join the journey with us by visiting
one of our bi-weekly industry Blogs
New functionality along with Enhanced Models to Deliver More Efficient and Comprehensive Predictions in Chemical Safety
Instem Secures Portion of €2.5m Grant as Member of Research Consortium Investigating the Mutagenicity of N-nitrosamines
Newly Added Services to Support Latest Regulatory Guidance and Growing Demand for Alternative Testing Methods
To help you better evaluate our software or services, we believe an initial, no pressure Web session is the way to go.
© 2023 Instem Group of Companies